Latest Breaking News On - Group chief medical officer - Page 2 : comparemela.com

Telix Completes Proof-of-Concept Study of TLX592 Targeted

Telix Completes Proof-of-Concept Study of TLX592 Targeted
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

United statesKyahn williamsonDavidn cadeCorporate communicationsDrug administrationHealth canadaAustralian therapeutic goods administrationTelix pharmaceuticals limitedTelix pharmaceuticalsTelix pharmaceuticals limited disclosure committeeAustralian securities exchangePharmaceuticals limitedPositron emission tomographyGroup chief medical officer

Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer

Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesKyahn williamsonDavidn cadeTelix pharmaceuticals limitedAustralian securities exchangeTelix pharmaceuticals limited disclosure committeeTelix pharmaceuticalsDrug administrationCorporate communicationsHealth canadaAustralian therapeutic goods administrationCompletes proof of concept studyAlpha therapyPharmaceuticals limitedPositron emission tomographyGroup chief medical officer

Telix Pharmaceuticals Limited: Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer

CUPID is a Phase I safety and dosimetry study of TLX592, Telix's investigational antibody-based targeted alpha therapy for prostate cancer.Establishes proof-of-concept for Telix's proprietary

United statesDavidn cadeKyahn williamsonTelix pharmaceuticals limitedCorporate communicationsTelix pharmaceuticals limited disclosure committeeHealth canadaAustralian therapeutic goods administrationAustralian securities exchangeTelix pharmaceuticalsDrug administrationPrnewswire telix pharmaceuticals limitedPharmaceuticals limitedPositron emission tomographyGroup chief medical officerIhr portfolio

Telix Completes Proof-Of-Concept Study Of TLX592 Targeted Alpha Therapy In Prostate Cancer

United statesKyahn williamsonDavidn cadeHealth canadaPrnewswire telix pharmaceuticals limitedDrug administrationAustralian securities exchangeTelix pharmaceuticals limited disclosure committeeTelix pharmaceuticalsTelix pharmaceuticals limitedCorporate communicationsAustralian therapeutic goods administrationPharmaceuticals limitedPositron emission tomographyGroup chief medical officer

TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation

TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation
balticbusinessnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from balticbusinessnews.com Daily Mail and Mail on Sunday newspapers.

United statesSan franciscoKyahn williamsonRichard valeixCdx pixclaraSteven chilinskiDavidn cadeTelix pharmaceuticalsPharmalogic holdings corpDrug administrationHealth canadaSociety for nuclear medicineTelix pharmaceuticals limitedTelix pharmaceuticals limited disclosure committeeUniversity of californiaCorporate communications